Surgery scientists, a specialized group within the medical and research community, play a pivotal role in advancing surgical practices and patient outcomes through rigorous scientific inquiry and innovative methodologies. These professionals are at the forefront of developing, testing, and implementing new surgical techniques, instruments, and technologies that enhance the precision, safety, and efficacy of surgical procedures. The field of surgical science is inherently multidisciplinary, drawing upon principles from biomedical engineering, materials science, pharmacology, and physiology to address complex surgical challenges.
This integrative approach enables surgery scientists to not only improve existing procedures but also to pioneer entirely new surgical paradigms. Recent advancements in surgical science have been driven by the advent of minimally invasive techniques, robotic surgery, and personalized medicine. These innovations have significantly reduced recovery times, minimized surgical risks, and tailored interventions to individual patient needs. Moreover, the incorporation of data analytics and artificial intelligence into surgical planning and execution has opened new avenues for precision surgery, allowing for real-time decision-making and enhanced surgical outcomes.
As the global burden of surgical diseases continues to rise, the role of surgery scientists becomes increasingly critical. Their research endeavors are essential in addressing the disparities in surgical care across different populations and regions, ensuring that cutting-edge surgical innovations are accessible and equitable. This research writeup delves into the current landscape of surgical science, highlighting key advancements, ongoing challenges, and future directions. By exploring the contributions of surgery scientists to the broader medical field, we aim to underscore the importance of their work in improving patient care and shaping the future of surgery.
Our team has been working on cardio-metabolic diseases, cardiac immunology, extracellular vesicles and nanomedicine. Our laboratory is working with various established pre-clinical animal models of human disease, including myocardial infarction, ischemia reperfusion injury, pressure overload, diet-induced heart failure), atherosclerosis and non-alcoholic fatty liver disease. The newly established NANONASH research program aims to tap unto brilliant and young scientists to develop new and effective nanomedicine-based therapies for the treatment of fatty liver disease. Our group also works on new nanomaterials and drug delivery systems (carrying small molecules, nucleic acids, RNAs etc) for translational research in cardiovascular disease, fatty liver disease and gut related disease. Our nanomedicine laboratory, the Centre for NanoMedicine, provides state-of-the-art technology to enable such research and expand the applications of nanomedicine for unmet clinical needs.